Pharmacogenomics in cardiovascular clinical trials

Area of Science:

• Genomics and Pharmacogenetics
• Clinical Medicine

Background:

• Genomics is rapidly advancing, transitioning from basic science to clinical medicine.
• Pharmacogenetics, while lacking specific regulatory guidelines, is integrated into existing drug development recommendations.
• Identifying genetic contributions to drug response requires careful consideration of disease context.

Purpose of the Study:

• To explore the role of pharmacogenetics in drug development.
• To highlight the importance of collecting genomic data from clinical trial participants.
• To inform physicians about genetic variability and its clinical implications.

Main Methods:

• Collecting genomic DNA from patients in clinical drug trials with consent.
• Performing post hoc analyses on collected genomic data.
• Considering disease classification, data collection methods, and disease process knowledge.

Main Results:

• Patients experiencing therapeutic failures or drug toxicity are key populations for pharmacogenomic analysis.
• Post hoc genomic analysis is valuable, with exceptions for genotype-excluded randomized patients.
• Understanding genetic variability and environmental interactions is crucial.

Conclusions:

• Genomic DNA collection in clinical trials supports pharmacogenetic research and personalized medicine.
• Pharmacogenomic insights can be gained from studying treatment outcomes, including adverse events.
• Physicians require education on genetic variability for effective patient care.